Targeted therapy in colorectal carcinoma: more than a theory

Colorectal Dis. 2008 Mar;10(3):209-18; discussion 218-221. doi: 10.1111/j.1463-1318.2008.01495.x.

Abstract

Objective: The aim of this review was to examine clinical trial data reporting the use of targeted therapies in colorectal cancer.

Method: Candidate trials were identified by a comprehensive literature search.

Results: The data on the use of targeted therapies; usually combined with chemotherapy in the treatment of colorectal cancer is accumulating rapidly. These new agents will increasingly become incorporated into standard treatment schedules.

Conclusion: Targeted therapy has moved rapidly from the laboratory to the clinic and is opening up potentially new and exciting areas for the development of the systemic treatment of colorectal cancer.

Publication types

  • Review

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Angiogenesis Inhibitors / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Cetuximab
  • Chemotherapy, Adjuvant
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / surgery
  • Combined Modality Therapy
  • Drug Delivery Systems / methods*
  • Female
  • Humans
  • Male
  • Prognosis
  • Randomized Controlled Trials as Topic
  • Survival Analysis
  • Treatment Outcome
  • Vascular Endothelial Growth Factor A / antagonists & inhibitors

Substances

  • Adjuvants, Immunologic
  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Vascular Endothelial Growth Factor A
  • Bevacizumab
  • Cetuximab